6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
described O
elsewhere O
in O
the O
prescribing O
information O
: O
* O
Hepatotoxicity B-OSE_Labeled_AE
[ O
see O
Contraindications O
( O
4.1 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Bone B-OSE_Labeled_AE
Marrow I-OSE_Labeled_AE
Effects I-OSE_Labeled_AE
/ O
Immunosuppression B-OSE_Labeled_AE
Potential/ O
Infections B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Peripheral B-OSE_Labeled_AE
Neuropathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Skin B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Increased B-OSE_Labeled_AE
Blood I-OSE_Labeled_AE
Pressure I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Respiratory B-OSE_Labeled_AE
Effects I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
> O
=10 O
% O
and O
> O
=2 O
% O
greater O
than O
placebo O
) O
: O
headache O
, O
diarrhea O
, O
nausea O
, O
alopecia O
, O
increase O
in O
ALT O
( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Genzyme O
Corporation O
at O
1-800-745-4447 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

A O
total O
of O
2047 O
patients O
receiving O
AUBAGIO O
( O
7 O
mg O
or O
14 O
mg O
once O
daily O
) O
constituted O
the O
safety O
population O
in O
the O
pooled O
analysis O
of O
placebo O
controlled O
studies O
in O
patients O
with O
relapsing B-Not_AE_Candidate
forms O
of O
multiple I-Not_AE_Candidate
sclerosis I-Not_AE_Candidate
; O
of O
these O
, O
71 O
% O
were O
female O
. O

The O
average O
age O
was O
37 O
years O
. O

Table O
1 O
lists O
adverse O
reactions O
in O
placebo-controlled O
trials O
with O
rates O
that O
were O
at O
least O
2 O
% O
for O
AUBAGIO O
patients O
and O
also O
at O
least O
2 O
% O
above O
the O
rate O
in O
placebo O
patients O
. O

The O
most O
common O
were O
headache B-OSE_Labeled_AE
, O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
, O
and O
nausea B-OSE_Labeled_AE
. O

The O
adverse O
reaction O
most O
commonly O
associated O
with O
discontinuation O
was O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
( O
3.3 O
% O
, O
2.6 O
% O
, O
and O
2.3 O
% O
of O
all O
patients O
in O
the O
AUBAGIO O
7 O
mg O
, O
AUBAGIO O
14 O
mg O
, O
and O
placebo O
treatment O
arms O
, O
respectively O
) O
. O

Table O
1 O
. O

Adverse O
Reactions O
in O
Pooled O
Placebo-Controlled O
Studies O
in O
Patients O
with O
Relapsing O
Forms O
of O
Multiple O
Sclerosis O
Adverse O
Reaction O
AUBAGIO O
7 O
mg O
( O
N=1045 O
) O
AUBAGIO O
14 O
mg O
( O
N=1002 O
) O
Placebo O
( O
N=997 O
) O
Headache B-OSE_Labeled_AE
18 O
% O
16 O
% O
15 O
% O
Increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Alanine I-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
13 O
% O
15 O
% O
9 O
% O
Diarrhea B-OSE_Labeled_AE
13 O
% O
14 O
% O
8 O
% O
Alopecia B-OSE_Labeled_AE
10 O
% O
13 O
% O
5 O
% O
Nausea B-OSE_Labeled_AE
8 O
% O
11 O
% O
7 O
% O
Paresthesia B-OSE_Labeled_AE
8 O
% O
9 O
% O
7 O
% O
Arthralgia B-OSE_Labeled_AE
8 O
% O
6 O
% O
5 O
% O
Neutropenia B-OSE_Labeled_AE
4 O
% O
6 O
% O
2 O
% O
Hypertension B-OSE_Labeled_AE
3 O
% O
4 O
% O
2 O
% O
Cardiovascular O
deaths O
Four O
cardiovascular B-NonOSE_AE
deaths B-NonOSE_AE
, O
including O
three O
sudden B-NonOSE_AE
deaths I-NonOSE_AE
, O
and O
one O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
in O
a O
patient O
with O
a O
history O
of O
hyperlipidemia B-Not_AE_Candidate
and O
hypertension B-Not_AE_Candidate
were O
reported O
among O
approximately O
2600 O
patients O
exposed O
to O
AUBAGIO O
in O
the O
premarketing O
database O
. O

These O
cardiovascular B-NonOSE_AE
deaths B-NonOSE_AE
occurred O
during O
uncontrolled O
extension O
studies O
, O
one O
to O
nine O
years O
after O
initiation O
of O
treatment O
. O

A O
relationship O
between O
AUBAGIO O
and O
cardiovascular B-NonOSE_AE
death B-NonOSE_AE
has O
not O
been O
established O
. O

Acute O
Renal O
Failure O
In O
placebo-controlled O
studies O
, O
creatinine B-OSE_Labeled_AE
values I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
more O
than O
100 O
% O
over O
baseline O
in O
8/1045 O
( O
0.8 O
% O
) O
patients O
in O
the O
7 O
mg O
AUBAGIO O
group O
and O
6/1002 O
( O
0.6 O
% O
) O
patients O
in O
the O
14 O
mg O
AUBAGIO O
group O
versus O
4/997 O
( O
0.4 O
% O
) O
patients O
in O
the O
placebo O
group O
. O

These O
elevations O
were O
transient O
. O

Some O
elevations O
were O
accompanied O
by O
hyperkalemia B-OSE_Labeled_AE
. O

AUBAGIO O
may O
cause O
acute B-OSE_Labeled_AE
uric I-OSE_Labeled_AE
acid I-OSE_Labeled_AE
nephropathy I-OSE_Labeled_AE
with O
transient O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
because O
AUBAGIO O
increases B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
uric I-OSE_Labeled_AE
acid I-OSE_Labeled_AE
clearance I-OSE_Labeled_AE
. O

Hypophosphatemia O
In O
clinical O
trials O
, O
18 O
% O
of O
AUBAGIO-treated O
patients O
had O
hypophosphatemia B-OSE_Labeled_AE
with O
serum B-OSE_Labeled_AE
phosphorus I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
of I-OSE_Labeled_AE
at I-OSE_Labeled_AE
least I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
mmol I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
, O
compared O
to O
7 O
% O
of O
placebo-treated O
patients O
; O
4 O
% O
of O
AUBAGIO-treated O
patients O
had O
hypophosphatemia B-OSE_Labeled_AE
with O
serum B-OSE_Labeled_AE
phosphorus I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
at I-OSE_Labeled_AE
least I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
mmol I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
but I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
mmol I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
, O
compared O
to O
0.8 O
% O
of O
placebo-treated O
patients O
. O

No O
patient O
in O
any O
treatment O
group O
had O
a O
serum B-NonOSE_AE
phosphorus I-NonOSE_AE
below I-NonOSE_AE
0 I-NonOSE_AE
. I-NonOSE_AE
3 I-NonOSE_AE
mmol I-NonOSE_AE
/ I-NonOSE_AE
L I-NonOSE_AE
. O

